Ongoing Trials in T-Cell Lymphomas

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Clinical Pearls:

• Researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas
• Vorinostat and romidepsin, which are the only two approved epigenetic therapies in this space, both have response rates close to 30%
• Activity remains to be seen in a phase I trial looking at the combination of romidepsin and 5-azacytidine
• Another trial is observing the activity of pralatrexate in combination with romidepsin